Summary
Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.
Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.
Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101069281 |
| Start date: | 01-10-2022 |
| End date: | 31-03-2024 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.
Status
SIGNEDCall topic
ERC-2022-POC1Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
